Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, 57 Changping Road, Shantou, 515041, China.
Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
ESC Heart Fail. 2021 Oct;8(5):3663-3689. doi: 10.1002/ehf2.13531. Epub 2021 Aug 9.
Takotsubo cardiomyopathy (TCM), characterized by reversible ventricular dysfunction, has similar mortality to acute coronary syndrome. With the growing interest in the diagnosis of and interventions for TCM, many risk factors had been found to affect the prognosis of TCM patients, such as age, sex, and pre-existing diseases. Because of the incomplete understanding of the pathophysiologic mechanism in TCM, evidence-based medical therapy for this condition is lacking. Early intervention on risk factors may improve the outcomes of TCM. In this review, we sought to provide up-to-date evidence on risk factors and medical therapies that affect TCM outcome. We found that male sex, physical triggers, and certain comorbidities such as chronic kidney disease, malignant disease, higher body mass index, sepsis, chronic obstructive pulmonary disease, and anaemia were associated with poor TCM prognosis. In contrast, race, hyperlipidaemia, diabetes mellitus, and mood disorders were not clearly associated with TCM prognosis. We also reviewed the effect of medical therapies on TCM outcome, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, calcium channel blockers, and statins. The evidence that these medications confer a survival benefit on TCM patients is limited. Understanding these prognostic factors could help develop risk-stratification tools for TCM and establish effective prevention and interventions for this not-so-benign condition. Further multicentre clinical studies with large samples and meta-analyses of findings from previous studies are needed to address the inconsistent findings among the many potential risk factors for TCM.
心尖球囊样综合征(TCM)以心室功能可逆性障碍为特征,其死亡率与急性冠状动脉综合征相当。随着对 TCM 诊断和干预的兴趣日益浓厚,许多影响 TCM 患者预后的危险因素被发现,如年龄、性别和既往疾病。由于对 TCM 病理生理机制的不完全了解,这种疾病缺乏循证医学治疗。早期干预危险因素可能会改善 TCM 的预后。在这篇综述中,我们旨在提供影响 TCM 结局的危险因素和医学治疗的最新证据。我们发现,男性、躯体性诱因以及某些合并症,如慢性肾脏病、恶性肿瘤、较高的体重指数、脓毒症、慢性阻塞性肺疾病和贫血,与 TCM 不良预后相关。相比之下,种族、高脂血症、糖尿病和情绪障碍与 TCM 预后无明显相关性。我们还回顾了医学治疗对 TCM 结局的影响,包括血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂、钙通道阻滞剂和他汀类药物。这些药物对 TCM 患者有生存获益的证据有限。了解这些预后因素有助于为 TCM 开发风险分层工具,并为这种并非良性的疾病建立有效的预防和干预措施。需要进行更多的多中心临床研究,以获得更大的样本量,并对以前研究的结果进行荟萃分析,以解决 TCM 许多潜在危险因素之间的不一致发现。